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ABSTRACT OF THE DISSERTATION
Reliability and Validity of the Outcome Questionnaire
in a Heterogeneous Cancer Population
by
Laura Testerman
Doctor of Philosophy, Graduate Program in Psychology
Loma Linda University, August 2012
Dr. Jason E. Owen, Chairperson
The Institute of Medicine (IOM) and National Cancer Comprehensive Network
(NCCN) now require integration of psychosocial care into the treatment of cancer
patients to identify, monitor, and treat psychosocial distress. Despite the widespread use
of Patient Reported Outcomes (PRO) for these purposes, no gold standard PRO for
assessing distress exists for psycho-oncology research and clinical practice. This study
examined the reliability, validity, and preliminary treatment effects of the Outcome
Questionnaire, a PRO never before been used or validated with heterogeneous cancer
patients. Adult cancer survivors were recruited nationwide to participate in an online
support group (N=187) and randomly assigned to a treatment or wait-list condition in a
longitudinal randomized controlled trial. The OQ Total Score demonstrated excellent
reliability (α = 0.92). However, the subscales varied in the quality of their reliability
ratings. Convergent validity was demonstrated, but divergent validity was not
adequately shown. Three new significant factors were identified through exploratory
factor analysis. For preliminary treatment effects in the online support group study, it
was shown that those with a worse perceived health status F (1, 90) = 7.48, p = 0.008 and
those who engaged more with the online support group improved over time F (1, 59) =
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6.00, p = 0.018. These findings suggest mixed support for the implementation of the OQ
as a PRO in a chronic disease sample. Generally, if the OQ is to be used as is within a
cancer population, the Total Score may be interpreted as both reliable and valid and able
to demonstrate treatment effects in a cancer population, but the subscale scores should
not be interpreted.
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CHAPTER ONE
INTRODUCTION
The Institute of Medicine (IOM) and National Cancer Comprehensive Network
(NCCN) now require integration of psychosocial care into the treatment of cancer
patients to identify, monitor, and treat psychosocial distress ("Distress Management
Clinical Practice Guidelines in Oncology," 2010). Cancer patients experience
significant levels of psychosocial distress related to numerous cancer and patient-related
factors (Nicholas & Veach, 2000). Treatment outcome evaluation of both currently
utilized and newly developed psychosocial treatments is one way to ensure that a high
quality standard of care is being provided. Measuring the effectiveness and impact of an
intervention or treatment via change in psychosocial distress from baseline to a followup timepoint is an integral part of outcome measurement. These measurements are
normally assessed using patient reported outcome measurements (PROs). Despite the
widespread use of PROs for this purpose, no gold standard PRO for assessing distress
exists for psycho-oncology research and clinical practice. Many of the current PROs
suffer from a variety of psychometric issues and it is often the case that measures
employed in research settings are not widely used in clinical settings and vice versa
(Luckett, et al., 2010). A potential solution is to utilize the Outcome Questionnaire (OQ:
Lambert, et al., 1996), a popular clinical outcome measure that has extensive use within
general psychotherapy outcome research. The OQ, despite its many potential benefits,
has never before been used or validated within a chronic disease population such as with
heterogeneous cancer patients. The OQ may be advantageous in this population due to
its content, sound psychometric properties, sensitivity to change, successful track record
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of finding treatment effects, clinically meaningful interpretation, and practical
administration.

Cancer: Psychosocial Concerns
Brief History of Psychosocial Care in Cancer Patients
Cancer patient psychosocial care has not always been valued nor provided within
the medical community. Neither the Patient’s Bill of Rights nor the Joint Commission
on Accreditation of Healthcare Organizations has mandated treatment for these
concerns. Not until 1997, when the NCCN formed an interdisciplinary panel, consisting
of oncologists, psychiatrists, nurses, psychologists, social workers, clergy, and patient
advocates, were formal clinical practice guidelines for cancer patient psychosocial care
developed. The benchmark publication in 1999 of these first guidelines for managing
cancer patient distress included recommendations for identification, monitoring, and
treatment of distress at all stages of cancer via screening for distress and psychosocial
problems, creating and implementing a treatment plan for the identified problems,
referring to appropriate psychosocial services as needed, and reevaluating the patient as
necessary ("Distress Management Clinical Practice Guidelines in Oncology,” 2010).
Effective treatment of cancer patient psychosocial distress is the ultimate goal of these
standards. These guidelines laid the groundwork for the IOM report on Cancer Care for
the Whole Patient (Cancer care for the whole patient: Meeting psychosocial health
needs, 2007) which supported the NCCN guidelines and established the necessity for
psychosocial care as an integral standard for quality cancer patient care.
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NCCN guidelines recommend specific psychosocial screening measurement
procedures for identification of distress but have not yet standardized outcome
assessment of distress treatment. Screening is a separate and distinct process from
assessment of distress (Nicholas & Veach, 2000; Zabora, 1998). It is considered a quick
way for professionals to identify patients with psychosocial distress and to refer them for
further assessment and treatment if scores meet a critical cut-point (Zabora, SmithWilson, Fetting, & Enterline, 1990). The NCCN recommends screening via a one-item,
visual self-report questionnaire, the Distress Thermometer (DT), and an accompanying
36-item problem checklist that the patient completes in the waiting room. The problem
checklist asks patients to endorse problems in five categories: practical, family,
emotional, spiritual/religious, and physical. The DT (Roth, et al., 1998), a one-item
measure, reads, “How distressed have you been during the past week on a scale of 0 to
10,” and depicts a visual thermometer with a 0– 10 scale that ranges from “no distress”
(0) to “extreme distress” (10). Significant distress is indicated by scores four or higher.
A score below four is not indicated for treatment or referral and at this level the primary
oncology team typically self-manages distress via supportive care assistance. Mild
distress is considered to be in the range from 4-5, moderate distress ranges from 6-7, and
8 or more is considered severe distress. If a patient scores in any of these ranges, the
NCCN recommends that the nurse review the accompanying problem checklist, identify
core concern areas, and refer the patient to appropriate resources for treatment, including
a mental health professional, social worker, or chaplaincy service.
Assessment is a more in-depth evaluative process performed within the
guidelines of the treating professionals’ clinical practice. For psychological mental
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health professionals, the NCCN guidelines recommend a psychological evaluation that
includes an assessment of the nature of the presenting problem of psychosocial distress,
psychiatric history, decision-making ability, suicidality, and symptoms and behaviors
surrounding pain, fatigue, sleep, sexuality, or other relevant physical ailments ("Distress
Management Clinical Practice Guidelines in Oncology,” 2010). Once assessed, the
health professional begins treatment. Currently, the quality of psychological treatment
received is not monitored with any level of measurement. The necessity for this type of
evaluation is additionally supported by the NCCN, which identified the need for clinical
health outcomes measurements to incorporate assessment of the psychosocial domain
("Distress Management Clinical Practice Guidelines in Oncology,” 2010). One option
for monitoring the quality of treatment provided is via the use of a PRO measure, the
OQ, which will be discussed in more depth later.

Importance of Distress Treatment
Early identification, assessment, and treatment of distress may benefit the
patient, family, doctor, and the healthcare team. Successful treatment of distress reduces
healthcare costs and can improve quality of life (QOL) (Allison, et al., 1995; Deshields,
Tibbs, Fan, & Taylor, 2006; Skarstein, Aass, Fossa, Skovlund, & Dahl, 2000).
Increased distress may lead to reduction of some health behaviors needed for cancer
prevention (Loscalzo & Brintzenhofeszoc, 1998; Pearlin & Schooler, 1978; Schou,
Ekeberg, Ruland, Sandvik, & Karesen, 2004), delay in treatment seeking (Loscalzo &
Brintzenhofeszoc, 1998; Pearlin & Schooler, 1978; Schou, et al., 2004), deterioration of
doctor-patient communication ("Distress Management Clinical Practice Guidelines in
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Oncology,” 2010), reduction of satisfaction with treatment (VonEssen, Larsson, Oberg,
& Sjoden, 2002), increased treatment non-adherence (DiMatteo, Lepper, & Croghan,
2000; Kennard, et al., 2004), increased number of anxiety-related doctor visitations and
contacts ("Distress Management Clinical Practice Guidelines in Oncology,” 2010), and
increased risk for morbidity and mortality of cancer (Antoni, et al., 2006; Giese-Davis &
Spiegel, 2003; Spiegel & Giese-Davis, 2003). Additionally, distress has been highly
associated with decreased aspects of QOL, including physical, psychological, social, and
spiritual well-being, for cancer patients and survivors (Deshields, et al., 2006; Skarstein,
et al., 2000).
The sincere risk associated with distress can be further elucidated by a
metanalysis conducted by DiMatteo, Lepper, and Croghan (2000) which indicated that
nonadherence was three times greater in depressed patients than those who were not
depressed. These results are even more startling when placed in the context of general
nonadherence to drug treatment, for even non-depressed individuals frequently do not
comply with treatment. Findings have indicated that nearly half of cancer patients
lacked compliance to an oral medication in the fourth year of treatment, indicating that
over 25% may not gain the dosage necessary for a clinically positive outcome
(Partridge, Wang, Winer, & Avorn, 2003). Sadly, many more depressed individuals
may fall into this negative outcome category, increasing risk of morbidity and mortality.
Evidently, improving treatment of distress is vital. An understanding of the prevalence,
predictors, and nature of psychosocial distress cancer patients experience is helpful to
understanding measurement of cancer patient distress that can ultimately identify
efficacious and effective distress interventions.
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Psychosocial Distress
Cancer patients not only have to endure physical symptoms related to their
disease, but also high levels of psychosocial distress (Derogatis, Morrow, Fetting, & al.,
1983; Farber, Weinerman, & Kuypers, 1984; Stefanek, Derogatis, & Shaw, 1987).
Psychosocial distress is common across the trajectory of the illness as well as during
survivorship, frequently arising after diagnosis, at the onset or conclusion of treatment,
periodically throughout treatment, at recurrence, and when shifting into palliative care,
("Distress Management Clinical Practice Guidelines in Oncology,” 2010). The NCCN
guidelines define cancer patient psychosocial distress as:
“a multifactorial unpleasant emotional experience of a psychological, social,
and/or spiritual nature that may interfere with the ability to cope effectively with
cancer, its physical symptoms, and its treatment. Distress extends along a
continuum, ranging from common normal feelings of vulnerability, sadness, and
fears to problems that can become disabling, such as depression, anxiety, panic,
social isolation, and existential and spiritual crisis.” ("Distress Management
Clinical Practice Guidelines in Oncology,” 2010)
Thus, psychosocial distress encompasses issues of an emotional, psychological,
spiritual, and social nature, including typical stress reactions as well as diagnosable
mental disorders that may impede capability of dealing with cancer. The terminology
“distress” was particularly selected by the NCCN in order to reduce stigma or
embarrassment that may stem from use of the words “psychiatric” or “emotional.”
Because clinicians opened up dialogue regarding patient pain by using a simple selfreport question, asking patients to assess their pain on a zero to ten scale, they felt that
similarly it would be less offending to ask a patient to report “distress” on a zero to ten
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scale. Thus, the word “distress” was chosen because it can be defined and measured
with self-report instruments.
Thus, distress is both psychological and social in nature. Because of the
psychosocial nature of distress, many studies use the terminology “distress” and “quality
of life” somewhat interchangeably, or create additional distinctions that do not exist
between them, although neither approach is entirely accurate. The definition for QOL is
reportedly difficult to define (Bottomley, 2002) and has many overlapping
characteristics with psychosocial distress. QOL includes a larger overarching
framework of well-being in physical, social, cognitive, spiritual, emotional, and role
functioning areas (for example see Carlson & Bultz, 2003). However, many studies of
distress elect not to focus on any social issues of psychosocial distress, feeling that they
are impinging on the realm of QOL, despite the definition of distress including social
aspects (Carlson & Bultz, 2003). Thus, many studies may not be appropriately gauging
the totality of the experience of psychosocial distress. Ganz and Goodwin (2005) make
the argument that the best measurement of psychosocial interventions is via examining
psychosocial distress. They state that this may include measuring aspects of QOL (i.e.
social aspects) without measuring the totality of QOL itself. Thus, this study will
include a focus on the nature, prevalence, predictors, and outcome measurement of
psychosocial distress without focusing on the totality of QOL.
Distress can be measured across a continuum, ranging from normal adjustment,
to adjustment disorders, to subthreshhold mental disorders, to diagnosable mental
disorders (America Psychiatric Association, 2000). Typically at the time of diagnosis
most individuals experience normal adjustment, or “expected distress,” symptoms.

7

These may consist of feelings of fear, loss, worry, anger, and uncertainty about the
future and control over the world. Also, troubles with sleep, lack of appetite, trouble
focusing, and preoccupation with cancer, death, and treatment/side effects may arise.
The patient’s oncology team often handles mild distress. More pervasive and intense
symptoms are indicative of moderate to severe levels of distress that are frequently
referred to be treated by a mental health professional. These symptoms include extreme
worries, fears, sadness, despair, hopelessness, suicidality, family issues, and existential
or spiritual problems ("Distress Management Clinical Practice Guidelines in Oncology,”
2010).
More severe problems and symptoms will fall along the continuum ranging from
adjustment disorders to mental disorder diagnosis ("Distress Management Clinical
Practice Guidelines in Oncology,” 2010). To be diagnosed, adjustment disorders must
occur within three months of the onset of a stressor and represent a maladaptive reaction
or an inability to cope that has some marked effects on one’s ability to function at
school, home, and/or work (America Psychiatric Association, 2000). If mood and
anxiety symptoms become more pervasive and severe or persist beyond six months, a
more severe diagnosis may be indicated.
Depressive disorders are more severe mood disorder diagnoses and also a
common problem for cancer patients. Many symptoms caused by the disease and/or
treatment of cancer are identical to the symptoms necessary to meet criteria for
diagnosis of depression, thus, making it more difficult to distinguish the mood disorder.
Psychomotor retardation, appetite suppression, sleep disturbance, fatigue, concentration
difficulties, and apathy are frequent symptoms in cancer and its treatment that also
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imitate the mood disorder symptoms. Distinctive symptoms for diagnosing a comorbid
mood disorder include feelings of dysphoria and anhedonia, worthlessness,
hopelessness, excessive or inappropriate guilt, and/or suicidal ideation (J.C. Holland &
Alici, 2010). Suicidal ideation in cancer patients occurs across all stages of the disease
and is thought to act as a means for an individual to gain some sense of control over the
illness (J.C. Holland & Gooen-Piels, 2003). The risk of suicide is approximately two
times that of the normal population (Breitbart, Lederberg, Rueda-Lara, & Alici, 2009;
Chochinov, Wilson, Enns, & Lander, 1998), and an international population-based study
indicated that the risk remained elevated even up to 25-years after a cancer diagnosis
(Schairer, et al., 2006). Thus, untreated distress can be deadly.
In addition to depressive disorders, cancer patients commonly react with anxiety
that is manifested physically as well as in thoughts and behaviors. Holland and Alici
(2010) reviewed the literature that discussed the most common types of anxiety
disorders existing in cancer patients and indicated the following diagnoses: acute stress
disorder, posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD),
panic attacks or disorder, specific phobias, anxiety disorder due to a general medical
condition, and substance-induced anxiety disorder.

Prevalence of Distress
Cancer patients experience significantly more psychosocial distress than other
chronic disease populations or healthy adults (Kaiser, Hartoonian, & Owen, 2010).
Studies on prevalence of distress indicate that one in three cancer patients will
experience levels of significant distress (Derogatis, et al., 1983; Farber, et al., 1984;
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Stefanek, et al., 1987), and depending on the study, a range of 5-47% of cancer patients
report significant distress levels (Carlson, et al., 2004; Derogatis, et al., 1983; “Distress
Management Clinical Practice Guidelines in Oncology," 2010; Kaiser, et al., 2010).
Farber and colleagues (1984), utilizing the Symptom Check List-90 (SCL-90), detected
34% of cancer patients with elevated distress. Stefanek et al. (1987) identified 28% of
cancer patients with distress after assessment with the Brief Symptom Inventory (BSI).
Zabora and colleagues, also using the BSI, sampled larger cancer populations in 1997
and 2001 (Zabora, et al., 1997; Zabora, BrintzenhofeSzoc, Curbow, Hooker, &
Piantadosi, 2001). In 1997, these researchers measured 386 patients from 12 American
cancer centers and found levels of distress at 35%. In 2001 they gathered information
from 4496 participants with 35.1% reporting distress.
The prevalence of psychiatric diagnoses in cancer patients has been reported to
be as high as approximately 50% ("Distress Management Clinical Practice Guidelines in
Oncology," 2010; J.C. Holland & Gooen-Piels, 2003; Massie, 2004). Depending on the
patient population and diagnostic criteria used, the majority of diagnoses include the
following disorders and prevalence: adjustment disorders (estimates of 2/3rds of all
diagnoses), depressive disorders (0-53%), and anxiety disorders (1-49%) (Derogatis, et
al., 1983; Harter, et al., 2001; J.C. Holland & Gooen-Piels, 2003; Sellick & Crooks,
1999; Van'T Spijker, Trijsburg, & Duivenvoordern, 1997; Zabora, et al., 2001).
Adjustment disorders with anxiety and/or depressed mood represent the most common
diagnoses for cancer patients (J.C. Holland & Alici, 2010). In one of the earliest studies
on psychiatric diagnosis in cancer patients, Derogatis and colleagues (1983) sampled
patients from across 3 cancer programs and found that 47% were classified with a
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Diagnostic and Statistical Manual of Mental Disorders (DSM) Axis I disorder based on
a psychiatric interview and assessment with the SCL-90. Approximately 1/3 of
individuals in his sample met criteria for adjustment disorder with anxious or depressed
mood, and 7% were severe enough to be classified with major depressive disorder
(MDD).
Inconsistent variations in distress across cancer patients are postulated to occur
for a number of reasons. Herschbach (2004), argues for a heterogeneous picture of
distress results based on cancer type, indicating that a complex picture of factors within
a cancer type may be more depictive than seeking general causes of distress across the
totality of cancer diagnoses. However, others argue that discrepancy in distress levels
and predictors across studies may occur due to a lack of consistent nomenclature,
measurement questionnaire, and different cut-off requirements for distress type and
classification (Casarett & Inouye, 2001; Herschbach, et al., 2004; Luckett, et al., 2010;
Massie, 2004).

Risk Factors for Distress
Correlates and predictors of distress, or risk factors for distress, may be
categorized into cancer and patient-derived variables (J. C. Holland, 1998). Nicholas
and Veach (2000), after reviewing the literature, describe cancer-derived variables as
those that refer to illness and treatment. Patient-derived characteristics consist of
demographic characteristics, past history, intrapersonal qualities, and interpersonal
relationships. The authors support the position that a combination of history and
demographic factors may influence the activation/perception of intrapersonal
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characteristics and interpersonal relationships leading to distress. A combination of the
patient-derived and cancer-derived variables can lead to either normal adjustment or to
experience of psychosocial distress. The cancer and patient-derived risk factors for
distress will be delineated.

Cancer-Derived Risk Factors
Holland and Alici (2010) summarized findings across the literature, and
surmised that most cancer patients experience general fear and worry about disease
reoccurrence, the future, current and/or potential symptoms from cancer and its
treatment (i.e. pain, fatigue, death), phobias of health and hospital related treatment
items (i.e. blood, needles), and anxiety induced by certain types of hormone-secreting
cancers or substances used to treat the disease. Research supporting cancer-derived
variables as risk factors for increased distress is prevalent, but also mixed in findings.
These risk factors include variables related to the disease, including cancer type, site,
stage, and prognosis; treatment, both type and phase; comorbid illness and health
factors; physical symptoms; and related disability processes that can result in
psychosocial stressors (Nicholas & Veach, 2000; Turner, Wooding, & Neil, 1998).
In 1999, Sellick and Crooks found that advanced stages of cancer, physical
disability, and pain increased MDD. Contrary to Sellick and Crook’s disease stageMDD relationship, Zabora (1997) found no correlation between stage of cancer and
distress with the exception of the terminal phase, which indicated increased levels of
distress. Additionally, after sampling 4496 patients in 2001, Zabora et al. noted that
distress rate varied by cancer type, with the following types reporting the most to least
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distress: lung cancer (43.4)%, brain, Hodgkin’s disease, pancreas, lymphoma, liver, head
and neck, breast, leukemia, melanoma, colon, prostate, and gynecological (29.6%).
Similarly, Carlson et al. (2004) found that certain types of cancer patients reported the
highest levels of distress, specifically lung, pancreatic, head and neck, Hodgkin’s
disease, and brain cancer patients. However, her findings differed from both Sellick and
Crooks and Zabora et al.’s results, for her study indicated that active treatment patients
were currently the most distressed. Other findings demonstrated that fair or poor health
status, experiencing pain, comorbid conditions (Kaiser, et al., 2010), duration of illness,
and inpatient or outpatient setting (Herschbach, et al., 2004) are risk factors for distress.
Disability processes related to the disease and treatment also are risk factors for
psychosocial distress. The side effects of the treatment or illness may cause disruptions
in patients’ daily activities and daily functioning, causing a shift for cancer patients’
roles in work, play, home, and love life (Dodd, et al., 2001; Lutgendorf, et al., 2000;
Morasso, et al., 2001). These shifts may lead to distress within the patient as well as the
family as everyone experiences consequential shifts in their roles, structure, and needs at
home and work (Hewitt, Greenfield, & Stovall, 2005). Financial burden occurs as the
patient’s employment status and healthcare costs may lead to depleted funds (Hewitt, et
al., 2005). In addition, intimacy and sexual functioning between patient and partner is
frequently decreased (Aziz & Rowland, 2003). With all of these substantial changes in
functioning, survivors may struggle with indecision for how to move forward in their
careers and/or intimate relationships (Hewitt, et al., 2005).
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Patient-Derived Risk Factors
Findings from patient-derived demographic variables as risk factors for distress
are also prevalent. Demographic risk factors commonly include age, gender,
relationship status, and socioeconomic status (SES) (Nicholas & Veach, 2000).
Research in this area has expanded over the past years, and a variety of studies indicate
complicated findings for the significance of many of the following demographic
predictors for increased distress in cancer patients: female gender, younger age, being
unmarried, lower SES, lower levels of education, racial minority, higher number of
children in the household, lower number of elders in the household, and lack of health
insurance (Carlson, et al., 2004; Harter, et al., 2001; Herschbach, et al., 2004; Kaiser, et
al., 2010; Zabora, et al., 2001).
Patient-derived factors stemming from past history compose many other risk
factors for distress. Examples given of past history risk factors include prior mental
disorders, substance abuse, and social history (Nicholas & Veach, 2000). Turner,
Wooding, and Neil (1998) reviewed the literature on breast cancer from 1986-1996 and
deduced many risk factors for distress, including history of psychological problems.
Prior psychiatric history is typically associated with a diagnosis of anxiety or depression
at some point during the cancer disease trajectory. One study noted a previous history of
depression in 31.5% of women that were diagnosed with early breast cancer and a
comorbid depressive disorder (Kissane, et al., 1998). The NCCN review provides a
number of other problematic risk factors, including pre-morbid substance or alcohol
abuse and previous physical or sexual abuse. Additionally, pre-existing social
relationship history may be influential. Turner and colleague’s (1998) review identified
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recent loss of a spouse, marital problems, divorce, or widowhood, as increasing distress
levels.
Intrapersonal variables, such as personality and coping styles, and interpersonal
patient variables, such as social support, are also identified as risk factors. These factors
individually or combined may influence the experience of distress. High trait anxiety
(Love, 2004), pessimism (Pinquart, Frohlich, & Silbereisen, 2007), an avoidant coping
style, and/or unwillingness to disclose emotions (Turner, et al., 1998) are demonstrated
to be influential in increasing distress. Lack of social support, or perceived lack of
support, is also a risk factor for psychosocial distress (Turner, et al., 1998). Cancer
patients may experience loneliness and isolation (Aziz & Rowland, 2003), and those
living alone and who have communication barriers are also subject to higher degrees of
distress ("Distress Management Clinical Practice Guidelines in Oncology," 2010). Low
perception of social support by those living alone and/or those exhibiting depressive
coping behavior were associated with poorer adjustment (Sollner, et al., 1999).

Patient Reported Outcomes
Evidently, psychosocial distress is prevalent with numerous predictors related to
the disease and the patient. As discussed prior, although current NCCN guidelines
require treatment for psychosocial distress, they do not monitor the outcome of
treatment received. Additionally, new and improved psychosocial treatments and
interventions tested in epidemiological and clinical cancer studies need to be evaluated
for their outcome effects. Outcome evaluation of both currently utilized and newly
developed psychosocial treatments is one way to ensure that a quality standard of care is
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provided. The necessity for this type of evaluation is additionally supported by the
NCCN, which identified the need for clinical health outcomes measurements to
incorporate assessment of the psychosocial domain ("Distress Management Clinical
Practice Guidelines in Oncology," 2010). Key to this type of research is measurement of
outcome of psychosocial distress, most frequently assessed with PROs.
Increasingly over the previous decades, PROs are serving as the core assessment
for subjective concerns ("Distress Management Clinical Practice Guidelines in
Oncology," 2010), such as anxiety, depression, distress, and QOL. These measures are
used to improve understanding of the outcome of treatments in supportive care and
cancer treatment (Garcia, et al., 2007). PROs are frequently being offered as paper-andpencil-based, self-report questionnaires or electronically as ePROs (Abernethy, et al.,
2010). This self-report method has developed as an alternative to resource intensive
clinical diagnostic interviews, for a wide variety of continuous data can be easily
measured for those experiencing a wide range of severity of symptoms, from low to high
severity (Luckett, et al., 2010). Additionally, many PROs are now mandated for certain
clinical trials as essential outcome assessments that contribute to clinical decisionmaking. For example, PROs could have contributed to clinical decision-making for a
RCT comparing two leukemia treatments. One treatment significantly improved QOL
compared to another (Efficace, et al., 2008). Thus, information gleaned from PROs may
also provide a more complete picture of a patient and thus improve treatment (Efficace,
Vignetti, & Mandelli, 2009).
Despite the increasing reliance on PROs in psycho-oncology research, no goldstandard PRO currently exists to measure anxiety, depression, distress, and QOL across

16

cancer patients (Luckett, et al., 2010). Flynn et al. (2006) summarized the concerns
from qualitative interviews from 42 primary authors of clinical trials, including 11
oncology researchers, published in top-tier journals. They stated that the first problem is
that clinical trials use different PROs to address identical constructs, making it difficult
to compare findings across studies. Second, many PROs suffer from problematic
psychometrics. Many have not been validated within cancer populations, are not
sensitive to change, and suffer from floor or ceiling effects that minimize effect of a
treatment intervention. Third, many PROs are a burden for patients and administrators
to complete or score.
Additionally, many PROs measuring distress do not meet American
Psychological Association (APA) standards for outcome measurement decided by the
1994 APA-sponsored conference on developing outcome batteries (Horowitz, Lambert,
& Strupp, 1994). The group of 20 noted experts determined that the patient’s subjective
distress, psychological symptoms, and impairment in social functioning (i.e., work,
interpersonal relationships, etc.) were all necessary for appropriately measuring each
patient’s unique problems. Most PROS either assess psychological symptom distress or
social distress, but not both processes (Jong, et al., 2007).
Luckett and colleagues (2010) performed the first comprehensive oncology
measurement outcome review. These authors delineated guidelines for optimal PROs
utilized within psycho-oncology research. First, PROs need to have appropriate content
and be shown to be suitable for a heterogeneous cancer population with people in
varying types and stages of treatment. Second, optimal PROs need to demonstrate
sound psychometric properties including reliability and validity in English-speaking
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cancer patients. Most importantly, the measure needs to be sensitive to change. Third,
the track record of the measure is key. The measure needs to have a history of finding
treatment effects in randomized controlled trials (RCTs) of psychosocial interventions.
Fourth, the measure needs to be interpretable. Scores need to be clinically meaningful
and comparison data needs to be available from both cancer and general populations.
Finally, practical issues are key to a PRO being optimal. A brief, low-cost measure
available in many languages is ideal. The PRO needs to be efficient in its length—
minimizing item number and maximizing constructs assessed, thus having minimal
patient burden. Next, the measure needs to have minimal administration and scoring
burden.
With these guidelines in mind, Luckett et al. (2010) evaluated publications
between 1999 and May 2009 for numerous distress outcome questionnaires currently
used to measure anxiety, depression, and distress. These assessments have all been
applied during psychosocial intervention RCTs within English-speaking, heterogeneous
cancer populations. They chose to exclude PROs that solely measured the psychological
constructs of coping, adjustment, self-esteem, PTSD, and QOL. Also excluded were
measures that had one-third or greater of its items designated to measure somatic
concerns or health preoccupation. However, they included measurements that assessed
a combination of anxiety, depression, and distress. A total of 30 PROs were compared.
The top three ranked scales in order of suggestion included the Hospital Anxiety and
Depression Scale (HADS) (Zigmond & Snaith, 1983), the brief Profile of Mood States
(POMS), the POMS-37 (Shachem, 1983), and the original POMS-65 (McNair &
Heuchert, 2003) and the Center for Epidemiological Studies Depression Scale (CES-D)
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(Radloff, 1977) tied for third. However, none of these measures are commonly utilized
within clinical practice settings. Also, even after promoting these as the most optimal
assessments, Luckett and colleagues still had reservations about these measurements.
These measures and reservations based on the Luckett et al. findings will be outlined.
The HADS (Zigmond & Snaith, 1983) is a 14-item measure rated on a four-point
Likert scale asking patients to recall symptoms for the past seven days. It takes
approximately two to five minutes to complete. The cost is approximately $40 for the
manual and 90 cents per patient form. Subscale anxiety and depression scores are
available, and the total score is seen as an “unofficial” score. Although it ranked well in
terms of its psychometric reliability and validity as well as its efficiency at measuring
numerous constructs with only 14-items, there are problems involving the HADS overall
score (HADS-T), content, and appropriate cut-offs. Each problem within the HADS
will be briefly discussed.
Despite the HADS manual advising against utilizing the HADS total (HADS-T)
score as an overall measure of distress (Snaith & Zigmond, 1994), many researchers
continue to do so. Content analysis of the HADS anxiety (HADS-A) and depression
(HADS-D) scale indicate that only three items assess emotional experiences other than
criteria necessary for GAD and MDD. Therefore, positive findings for the HADS-T as
an overall measure of distress are mixed, with some results indicating its superiority
over the HADS-A and HADS-D in detecting clinically significant distress (Chaturvedi,
1991; Katz, Kopek, Waldron, Devins, & Tomlinson, 2004; Le Fevre, Devereux, Smith,
Lawrie, & Cornbleet, 1999; Lloyd-Williams, Friedman, & Rudd, 2001; Smith, et al.,
2006). However, factor analyses demonstrated mixed results (Johnston, Pollard, &
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Hennessey, 2000; Moorey, et al., 1991; Rodgers, Martin, Morse, Kendell, & Verill,
2005; Smith, et al., 2002). Additionally, RCTs were not utilized enough in the study to
indicate the sensitivity to change of the HADS-T over time. Luckett (2010) advised that
further psychometric assessment of the HADS-T is needed.
The content of the HADS also has several problems. First, somatic content is
completely omitted in hopes of reducing confounding disease and mood symptoms;
however, this creates an overemphasis on symptoms of anhedonia. Thus, the measure
was not as valid within late-stage cancer as well as depressive disorders, for it may lack
sensitivity to mild depression or adjustment disorder with depressed mood (LloydWilliams, et al., 2001; Love, 2004). Thus, the measure may not be the most sensitive to
changes that occur post-intervention, and it may not demonstrate true treatment
outcomes for some of these individuals.
Lastly, the recommended cut-off scores by the HADS creators do not always
perform well across studies, and optimal cut-off scores have differed (OHall, A-Hern, &
Fallowfield, 1999). Additionally, reporting of outcomes of the HADS sometimes takes
different forms, such as means and standard deviations, and only sometimes with
reference to cut-off scores. Also, more research is necessary to determine an optimal
cut-score for the HADS-T. These cut-off score problems make clinically meaningful
interpretation of the HADS very difficult. It also becomes problematic to compare
treatment effects across studies.
The POMS-37 is a 37-item measure rated on a five-point Likert scale, asking
participants to recall symptoms over the past seven days. It takes approximately five
minutes to complete and is free for non-commercial use. It includes measures of
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tension-anxiety, depression-dejection, anger-hostility, vigor, fatigue-inertia, and
confusion-bewilderment. A total mood disturbance score and individual subscale scores
are available. However, in the Luckett et al. (2010) study the total mood disturbance
score was not counted as a distress measure because the score is calculated via addition
of numerous subscales that included too many confounding somatic variables. Luckett
and colleagues noted the POMS-37 has a few significant problems including content and
track record. First, the measure was not created to screen for psychological disorders,
but only to assess for mood. Although it eases administrator cost and performs well for
anxiety and mixed affective disorders, it does not offer a suitable index of general
distress nor is it a good measure of depression for it also overemphasizes anhedonia.
Second, it has only been utilized in one RCT of psychosocial interventions to assess for
anxiety, depression, or distress since 1999 (Shachem, 1983). This limits the track record
for this instrument in finding significant psychosocial treatment effects.
The original POMS-65 is a 65-item measure rated on a five-point Likert scale
that asks participants to recall symptoms over the past seven days. It takes
approximately 10 minutes to complete. The manual costs $27 dollars and each measure
is $1.32. It includes measures of tension-anxiety, depression-dejection, anger-hostility,
vigor, fatigue-inertia, and confusion-bewilderment. A total mood disturbance score and
individual subscale scores are available. Like the Poms-37 in the Luckett et al. (2010)
study, the total mood disturbance score was not counted as a distress measure because
the score is calculated via addition of numerous subscales that included too many
confounding somatic variables. The POMS-65 is also less appealing due to its cost and
its length, and it is not perceived to be a very good measure of overall distress.
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Finally, the CES-D (Radloff, 1977) is a 20-item measures rated on a five-point
Likert scale based on the previous seven days. It takes approximately five minutes to
complete and is free for non-commercial use. It provides a total score of depression.
This measure is problematic for several reasons noted by Luckett et al. (2010). First, its
criterion validity has only been evaluated in two studies, and in one of these studies it
was outperformed by the HADS-T, which has psychometric issues that have already
been discussed. Furthermore, the cognitive burden of the CES-D was ranked in the midrange due to its questions assessing symptom frequency rather than severity. Finally,
the CES-D is not a good measure for anxiety and distress, and it is a lengthy measure
that examines only one construct.

Solution: Alternative PRO, the Outcome Questionnaire
Their conclusions demonstrate that an overall gold-standard measure for
measuring anxiety, depression, and distress in cancer patients does not currently exist in
the literature. Many problems inherent in prior PROs may be resolved by incorporating
the consistent use of a standardized psychological disturbance outcome measure in
psycho-oncology cancer research. One measure with laudable strength is the OQ
(Lambert, et al., 1996). The OQ is one of the top ten measures utilized in the United
States for clinically measuring outcome of general psychosocial distress and functioning
(Hatfield & Ogles, 2004). As discussed prior, Luckett and colleagues (2010) made
many recommendations for evaluating and appraising PROs as optimal. Content,
psychometric properties, track record, interpretability, and practical issues of the OQ are
all key to classifying it as an optimal PRO. These gold-standard PRO requirements will
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be further discussed in terms of how the OQ already meets many of these guidelines
and/or how the current study plans to fulfill any gaps in these standards.

OQ Content
Content of optimal PROs attempting to measure psychological distress should be
suitable for a heterogeneous cancer population (Luckett, et al., 2010). The OQ was
specifically designed to measure key constructs and components of outcomes in global
psychological distress and functioning. Despite never being utilized within a cancer
population, the OQ has been prominently used to measure general functioning and
distress in patient-focused psychotherapy outcome research (for examples see: Harmon,
et al., 2007; Lambert, Hansen, & Finch, 2001; Lambert, Harmon, Slade, Whipple, &
Hawkins, 2005; Okiishi, et al., 2006; Slade, Lambert, Harmon, Smart, & Bailey, 2008;
Whipple, et al., 2003). A brief description of the OQ and a discussion of the rationale
behind the measure’s item and domain selection may support its suitability for use as a
measure of psychosocial distress within cancer patients.

Description of the OQ
The OQ (Lambert, et al., 1996) measures the global functioning and
psychological disturbance of a client. The assessment is a 45-question, five-point Likert
scale self-report measure ranging from zero (never) to four (almost always), resulting in
scores that range from 0 to 180. Higher scores indicate a higher endorsement of
disturbance. Composed of three subscales, the OQ measures symptom distress (SD),
interpersonal relationships (IR), and social role performance (SR). Major symptoms of
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psychiatric disorders, especially anxiety and depression, are assessed in the first
subscale, Symptom Distress. The second subscale, Interpersonal Relationships,
measures satisfaction and problem areas of relationships. Satisfaction and ability to
function in primary roles such as in school, work, or home, are measured in the third
subscale, Social Role. The authors of the OQ argue that all three subscales contribute to
a total score that captures global functioning and distress.

Rationale Behind Item and Construct Selection
All items and construct domains utilized in the OQ were selected rationally and
empirically (Lambert, et al., 1996). The content of the OQ has extensive clinical use
and relevance, for the items and constructs were selected to examine three key domains:
psychological symptom distress, interpersonal relationship problems, and social role
functioning (Lambert, et al., 1996; Mueller, Lambert, & Burlingame, 1998; Umphress,
Lambert, Smart, Barlow, & Clouse, 1997). Mueller and colleagues (1998) noted how
these three domains were designed to conceptually capture the definition of “mental
disorder” given in the DSM (4th Edition):
Each of the mental disorders is conceptualized as a clinically significant
behavioral or psychological syndrome or pattern that occurs in an individual and
that is associated with present distress (e.g., a painful symptom) or disability
(i.e., impairment in one or more important areas of functioning). (American
Psychiatric Association, 1994, p. xxi)
Thus, these domains of outcome meet the standards for outcome measurement decided
by the 1994 APA-sponsored conference on developing outcome batteries: patient’s
subjective distress, psychological symptoms, and impairment in social functioning (i.e.,
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work, interpersonal relationships, etc.) (Horowitz, et al., 1994). These concerns were all
considered necessary for appropriately measuring each patient’s unique problems.
Most outcome measures pale in comparison by either assessing symptom distress or
functioning but not both processes (Jong, et al., 2007).
OQ researchers selected items to include in the Symptom Distress subscale based
on reviewing survey data regarding psychological symptom and diagnosis prevalence in
the U.S. population (Lambert, et al., 1996). Analysis of the 1988 National Institute of
Mental Health epidemiological questionnaire informed researchers that the most
consistent symptoms and diagnoses included anxiety and depressive disorders closely
followed by substance abuse problems (Regier, et al., 1988). Thus, the OQ was heavily
loaded with items that measure these symptoms. Item selection was based on fit of
items to current DSM criteria for these disorders, additional symptoms supported by the
literature, and statistical analysis (Lambert, et al., 1996). One limitation of the OQ is
that a few items that were selected to best represent common symptoms of depression
and anxiety may overlap with common physical problems due to cancer treatment side
effects (e.g., fatigue, concentration). However, without the inclusion of these items it
may overestimate the symptoms of anhedonia and suffer from floor or ceiling effects of
the score.
Lambert and colleagues (1996) argue that the Interpersonal Relationships
subscale domain was also founded upon research that indicates that, a) people consider
relationship satisfaction key to personal happiness (Andrews & Withey, 1974; Beiser,
1973 ; Blau, 1977; Diener, 1984; Veit & Ware, 1983) and, b) that interpersonal
problems are the most prominently addressed issues in therapy (Horowitz, 1979;
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Horowitz, Rosenberg, Baer, Ureno, & Villasenor, 1988). Individual items were created
based on marriage and family literature and research on patient-reported interpersonal
problems for those in therapy (Horowitz, et al., 1991). Items were thus selected in order
to assess relationship conflict, loneliness, inadequacy, and withdrawal.
Lastly, the social role performance domain was also included based on prior
research. Previous QOL research asserts that patient symptoms may influence their
ability to perform at work, at home, and in relationships. Satisfaction in personal and
professional roles is correlated strongly with QOL (Beiser, 1973 ; Blau, 1977; Veit &
Ware, 1983). Thus, items were created to assess patients’ degree of distress within tasks
associated with their play, work, and relationship roles.
Overall, the content of the OQ is supported by the prior effort that went into
developing the items and domains for assessing psychological distress and functioning.
In order to determine if it is fully suitable for a heterogeneous cancer population, the
psychometric properties will need to be closely examined within a sampling of these
patients.

OQ Psychometric Properties
Gold-standard PROs need to be shown to be reliable and valid within the
population that they purport to measure (Luckett, et al., 2010). Prior psychometric
studies have been conducted with the OQ in both normal and psychiatric patient
populations. Despite these prior studies, this measure has never before been validated in
any cancer population or other chronic disease sample. Examination of the previous
reliability and validity studies may, a) support the psychometric properties of this
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instrument and thus support its implementation within a cancer population, and b) give
some indication for how the OQ may function in a cancer population. These previous
reliability and validity studies will be described, with a highlight of the findings noted.
Based on these research findings, predictions will later be postulated regarding the
reliability and validity of the OQ in a cancer population.

Reliability
Lambert and colleagues (1996) conducted the cornerstone study of the reliability
of the OQ. Undergraduate (N=157) and psychotherapy patient populations (N=289)
were sampled to determine internal consistency of the OQ. Excellent internal
consistency was demonstrated for students and patients’ OQ total score (student/patient
α = .93) as well as the Symptom Distress scale score (student α = .92; patient α = .91).
The Interpersonal Relationships and Social Role scales, having greater variation in the
functioning assessed in their measurements, demonstrated poorer reliability
(Interpersonal Relationships: student/patient α = .74; Social Role: student α = .70;
patient α = .71). Undergraduate students (N=157) who received no therapeutic
treatment were tested a second time at three weeks post-baseline assessment to examine
test-retest reliability. Pearson product-moment correlation coefficients indicated
temporal-stability of the OQ over this time frame for the OQ total score (r=.84),
Symptom Distress (r=.78), Interpersonal Relationships (r=.80), Social Role (r=.82).
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Validity
Concurrent validity of the OQ has been examined in two key studies, Lambert et
al. (1996), which utilized an undergraduate population (N=238), and Umphress,
Lambert, Smart, Barlow, and Clouse (1997), which sampled counseling center clients
(n=53), community clinic patients (n=106), and an inpatient psychiatric population
(n=24). Both studies measured concurrent validity by computing Pearson productmoment correlations between the OQ total and subscale scores and the criterion
measures. Both studies indicated similar validity patterns within their results.
High levels of convergent validity were demonstrated across each study, for the
OQ total and subscale scores had significant validity coefficients (p < 0.05) with all
criterion measures. The studies used the same criterion measures, although the Lambert
et al. (1996) study utilized additional measures. Within the Lambert et al. (1996) study,
the General Severity Index (GSI) from the SCL-90-R, Beck Depression Inventory
(BDI), State-Trait Anxiety Inventory (STAI), Zung Self-Rating Depression Scale
(ZSDS), Zung Self-Rating Anxiety Scale (ZSAS), Taylor Manifest Anxiety Scale
(TMAS), Inventory of Interpersonal Problems (IIP), and Social Adjustment Scale (SAS)
were utilized as the criterion measures. As hypothesized, the OQ total score and
Symptom Distress subscale maintained moderate to high validity coefficients with all
criterion measures (Total OQ: r = .60-.88, Symptom Distress: r = .50-.89), with
depression (ZSDS, BDI), anxiety (TMAS, STAI, and ZSAS), and global distress (GSI)
demonstrating the strongest relationships. Despite subscale-criterion measure
hypotheses, the Interpersonal Relationships and Social Role subscales did not correlate
highest with their predicted respective measures, yet still correlated significantly with all
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applicable measures (Interpersonal Relationships: r =.44-.67; Social Role: r =.41-.71).
Umphress and colleagues (1997) criterion measures included only the GSI, IIP, and
SAS-revised. Again, although the OQ total and Symptom Distress subscale scores
correlated as predicted with the respective criterion measures (Total OQ: r = .66-.88,
Symptom Distress: r = .65-.92), the Interpersonal Relationships and Social Role
subscales did not, despite their significant validity coefficient scores across measures
(Interpersonal Relationships: r =.45-.69; Social Role: r =.53-.73).
Lambert et al. (1996), Umphress et al. (1997), Vermeersch, Lambert, and
Burlingame (2000) and Mueller, Lambert, and Burlingame (1998) each conducted
research relevant to the construct validity of the OQ. Multiple means of assessing
construct validity were utilized in these studies, including examination of the following:
the OQ’s sensitivity to change, a confirmatory factor analysis (CFA) of the subscales of
the OQ, and the OQ’s ability to discriminate between psychiatric patient and non-patient
populations.
OQ total and individual item score sensitivity to change were examined by
Lambert et al. (1996) and Vermeersch, Lambert, and Burlingame (2000) respectively.
Lambert and colleagues (1996) make the argument that the validity of a psychotherapy
outcome measure like the OQ rests on its ability to demonstrate change in the desired
direction following a therapeutic intervention. Thus, scores of those not receiving
psychotherapy would be expected to remain the same, however scores of those receiving
psychotherapy would be expected to change in the direction of improvement. Lambert
et al. (1996) demonstrated support for total and subscale score sensitivity to change after
examining data from 40 psychotherapy patients at baseline and after seven sessions of
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outpatient psychotherapy treatment. T-test comparison of pre and post-scores
demonstrated significant improvement for patients across the total score and subscales.
Expounding upon this idea, Vermeersch, Lambert, and Burlingame (2000) examined
item-level sensitivity to change in a control group of undergraduate students (n=284)
and an experimental group of individuals from four outpatient mental health groups
(n=1176). Results from hierarchical linear modeling indicated that the majority of items
were sensitive to change in the optimal direction following treatment.
Despite favorable results for the OQ’s sensitivity to change, outcome of the CFA
for the three subscales of the measure were not as preferable. Three factor analysis
models were assessed using a split-sample and cross-validating design (Mueller, et al.,
1998). Model 1 tested a three-factor solution using the original three subscales of the
OQ (Symptom Distress, Interpersonal Relationships, Social Role) as three oblique
factors. Model 2 analyzed a two-factor solution by examining two oblique factors—the
original Symptom Distress and a new second factor that combined the Interpersonal
Relationships and Social Role scales. Lastly, Model 3 assessed a single-factor solution
of all three original subscales. Findings indicated that all models had a relatively poor
fit. However, chi-square analysis of the models indicated that Model 1, the three-factor
solution, had a significantly better fit than the other models. Other researchers have
noted that the OQ may be examining one global distress factor, for the correlations
between the subscales are significant (Umphress, et al., 1997). Mueller and colleagues
(1998) recommended that exploratory factor analysis should be performed in other
patient populations. Thus, this will be a focus for the current study.
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Discriminant validity findings regarding the ability of the OQ to discriminate
patient and non-patient sample mean scores, examined by Lambert et al. (1996) and
Umphress et al. (1997), supported the construct validity for this measure. These studies
compared a normal community sample with patient populations sampled from several
types of mental health services centers. In both studies, patient populations scored
significantly higher on the OQ (x̅ = 67.6-99.9) than non-patient populations (x̅ = 42.348.16), with the most severe patient populations (outpatient, inpatient) scoring the
highest on the measure. Umphress et al. (1997) further discriminated within the patient
populations and noted a significant difference in pre-treatment total OQ scores for those
diagnosed with a coded DSM disorder (x = 85.3) compared to those with a V-code score
(x = 66.2). Additionally, the Symptom Distress and Social Role subscales were
significantly higher in those with a DSM disorder. Lambert and colleagues (1996)
determined sensitivity (SE) and specificity (SP) by comparing classification accuracy for
patient and nonpatient populations via the previously described 64-cutoff score. The
sensitivity index was .85, meaning that 85 out of 100 patients were correctly classified.
The specificity index was .74, indicating that 74 out of 100 nonpatients were correctly
classified.

OQ Track Record
In addition to content and psychometric properties suggesting suitability for a
cancer population, optimal PROs should have a history of finding treatment effects in
RCTs of psychosocial interventions. Although never before examined in a cancer
population, previous OQ research supports its ability to find treatment effects in RCTs.
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Utilized within patient-focused outcome research, the OQ has repeatedly demonstrated
significant treatment effects for this type of research. The patient-focused research
paradigm will be discussed as well as some of the significant findings demonstrated by
the OQ. Showing treatment effects of the OQ in a cancer population will be a focus for
the current study.

Theoretical Development of Patient-Focused Paradigm and
Utilization of the Outcome Questionnaire
Stemming partly from pressures of managed care third-party payers, consumers,
and mental health workers to quantitatively demonstrate the benefit of psychological
service, psychological outcome research originated. The patient-focused research
paradigm developed in response to limitations by various types of outcome research.
This paradigm, dominated by the use of OQ-data, directly answers the question of
whether the current client is being helped by the current treatment. Clinicians receive
current and consistent feedback on clients’ progress in therapy at every session (via the
OQ scores) so that clinicians may alter treatments and prescribed therapeutic attendance
as necessitated by the clients’ progress or lack thereof (Howard, Moras, Brill,
Martinovich, & Lutz, 1996).
The patient-focused research paradigm was partially founded on two rationales
or theories. First, this paradigm declares that patient progress is often predictable, and
positive or negative therapeutic outcome may be revealed in the first few sessions of
therapy (Lambert & Bergin, 1994). Thus, knowledge of patients’ level of distress and
progress from session to session may increase therapists’ abilities to predict those who
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may have a negative outcome. Second, this research method was also in part developed
using the rationale from the dose-response theory of therapy effectiveness. The doseresponse theory indicates a linear relationship between the log of session numbers and
the probability of patients’ positive progress. Thus, the higher the dosage (number of
therapy sessions), the better the response (patient progress) (Howard, Kopta, Krause, &
Orlinsky, 1986). Utilizing support from these theories, patient-focused researchers
assert that feedback given to therapists on patient progress may increase/decrease the
dose of therapy sessions or treatment, and thus better the outcome response (Lambert et
al., 2001; Lambert et al., 2002; Whipple et al., 2003; Hawkins et al., 2004).
The dose-response theory was also influential in developing a mathematical
equation to assist in giving accurate patient-progress feedback. Many patient-focused
researchers are using an algorithm computed by Finch, Lambert, and Schaajli (2001) to
identify clients at risk for having a negative outcome to therapy, or those clients who
may drop out before receiving therapeutic benefits. These algorithms use the clients’
intake level of distress (OQ-score) along with the change in OQ-score of client’s level of
distress at the indicated session. Next the client is classified on a range of functionality
in either a “functional” or “dysfunctional” range based on Jacobson and Truax’s (1992)
clinical significance definitions. The feedback provided by the algorithm informs
therapists if a client is making the expected amount of progress at a point in time to
receive a clinically significant outcome. Thus, patients may be labeled as on track (OT),
if they are progressing normally, or not on track (NOT), if their progress is poor.
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Significant Treatment Effects Found in RCTs via the OQ
Many patient-focused research studies have examined the development and
implementation of OQ-feedback systems that incorporate the use of the previously
mentioned algorithm that assesses progress and change (e.g., Hawkins, Lambert,
Vermeersch, Slade, & Tuttle, 2004; Lambert, Whipple, et al., 2001; Lambert, et al.,
2002 ; Whipple, et al., 2003). These studies use an assigned experimental condition
consisting of therapists that receive patient progress OQ-feedback (Fb), while the control
condition did not receive patient OQ-feedback (NFb). Each of these two conditions has
clients that are represented by two status classifications based on the algorithm—NOT
or OT. The combination of the treatment levels and status conditions creates the
following groups: NOT-NFb (client is not progressing as expected and therapist is not
receiving feedback), NOT-Fb (client is not making appropriate progress and therapist is
receiving feedback), OT-NFb (client is making expected progress and therapist is not
receiving feedback), OT-Fb (client is making expected progress and therapist is
receiving feedback). This is the basic crux for these RCTs, although many of the
patient-focused paradigm studies add enhanced types of feedback (e.g.,Hawkins, et al.,
2004; Whipple, et al., 2003).
The previous research conducted using the patient-focused paradigm indicates
some important clinical trends as well as demonstrates support for the OQ’s ability to
detect significant effect sizes. First, consistent feedback of patient’s level of functioning
and progress significantly improved overall patient functioning (measured by change in
OQ-score from baseline to last session) and therapeutic outcome and attendance.
Second, greater degrees of feedback and support contributed to more clinically
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significant changes in overall patient functioning and therapeutic outcome (measured by
change in OQ-score from baseline to last session). Thus, the OQ has consistently
demonstrated significant treatment effects in patient-focused outcome research.

OQ Interpretability
A gold-standard PRO needs to be easily interpretable, having both clinically
meaningful scores and comparison data available from both the desired population as
well as the general population (Luckett, et al., 2010). Prior research on the OQ has
demonstrated clinically meaningful interpretation of the OQ scores as well as
comparison data available for general and distressed populations.
The OQ was designed to assess distress/functioning of individuals suffering from
a broad array of V-Code, Axis-I, and Axis-II disorders, meaning that one can compare
patients across vastly different diagnoses (Jong, et al., 2007). Lambert et al. (1996)
examined the OQ to determine the scores for clinically significant change and for the
Reliable Change Index. People with scores that increase or decrease by 14 points are
seen as making “reliable change.” The cut-off score from functional to dysfunctional is
64 points, with higher scores being indicative of higher dysfunction. To be considered
“recovered,” one’s OQ score must decrease by at least 14 points and pass below the 64
cut-off score. “Improved” individuals have an OQ score that decreases by a minimum
of 14 points but does not fall below the 64 cut-off score. “No change” individuals’ score
does not fluctuate by more than 14 points. “Deteriorated” individuals must have an
increase in score by 14 or more points. Additionally, the OQ has been found to function
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similarly across age and gender for both the total score as well as the subscales
(Lambert, et al., 1996).

OQ Practical Issues
In addition to each of the aforementioned qualities of a potential gold-standard
PRO, practical issues of the measure such as ease of patient and administrator burden
are key. The OQ was designed as a low-cost measure with ease of administration and
scoring (Lambert, et al., 1996). The OQ can be given as a paper and pencil
questionnaire or on a computer/PDA. The creators of the OQ have developed a program
so that the OQ can be easily scored electronically. However, at 45-items, even the time
to score it by hand is minimal for an administrator. Thus, this measure is practical for
use in outcome research.

Current Study Aims and Hypotheses
The current study plans to further evaluate the properties of the OQ in order to
fulfill appropriate standards recommended for a gold-standard PRO utilized in a cancer
population.

Aim One
The first aim of the current study is to demonstrate the reliability of the OQ in a
cancer population. It is hypothesized that the OQ Total score and three subscales of the
OQ will demonstrate reliability using Cronbach’s alpha.
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Aim Two
The second aim of the current study is to demonstrate the concurrent and
construct validity of the OQ in a cancer population.
It is hypothesized that concurrent validity will be demonstrated by showing
convergent validity of the OQ total score and DT and the Functional Assessment of
Cancer Treatment-General (FACT-G); the Symptom Distress subscale and the CES-D
and Brief POMS; the Interpersonal Relationships subscale and the Social Support Scale
and the FACT-G; and the Social Role subscale with the Social Constraint Scale and
FACT-G. Additionally, the current study hypothesizes that concurrent validity will be
supported by divergent validity of the OQ Total score and the Impact of Events ScaleRevised (IES-R); the Symptom Distress subscale and Social Constraint Scale; the
Interpersonal Relationships subscale and the CES-D; and the Social Role subscale with
the Brief POMS. It is hypothesized that construct validity of the three domains of the
OQ will be demonstrated via an exploratory factor analysis.

Aim Three
The final purpose of the current study is to show preliminary treatment effects of
using the OQ in a cancer population. This will be examined in two ways. First it is
hypothesized that individuals who receive 12-weeks of treatment in an online support
group (OSG) will show a significant decrease in their scores from baseline to post-test.
However, it is postulated that individuals in a 12-week wait list for OSGs will show no
difference in their scores from a baseline testing of their OQ distress and their start time
in an OSG after a 12-week waiting interval. Second, it is hypothesized that all
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participants (treatment and control) will show a decrease in scores from the beginning of
treatment to post-treatment.
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CHAPTER TWO
METHODS
Participants
Participants were recruited primarily from the cancer registry at a cancer
treatment facility, Loma Linda University Medical Center (LLUMC). Additionally,
efforts were made to recruit nationally using a variety of methods, including informative
letters to health-care providers, flyers, newspaper advertisements, public service
announcements, and Internet-based advertising. Patients were considered eligible if they
met the following criteria: adult (age 18 and over), cancer diagnosis, distress > 3 (based
on DT’s 0-10 scale), English-language literate, and daily access to Internet.

Design and Procedures
LLUMC
Cancer patients’ contact information was compiled based on the listings in the
LLUMC cancer registry from July 2008 to July 2010. Individuals on the registry are
either diagnosed or treated for cancer at LLU during these years. Recruitment via a
cancer registry has been noted for raising some concerns as well as having obvious
benefits for researchers and patients (Beskow, Sandler, & Weinberger, 2006). While
allowing access to a particular population, privacy regulation has been a noted issue for
registry members. However, the information gained via studies that utilize the registry
recruitment methods has the potential to benefit registry members. Rules, requirements,
methods, and strategies for using a cancer registry have varied by registry and state.
The most common approach allows researchers to notify physicians regarding their
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study, receive contact information of participants via the cancer registry, and finally
invite registry participants to participate in the study with an opt-out approach (Beskow,
et al., 2006). Other registries allow direct contact with registry members under the
autonomy principle of human subjects protections (i.e., patients themselves are better
judges of whether a study is of interest to them than would be their physician). This
approach was most similar to what was utilized in the current study as patients were
directly contacted and invited to participate.
Cancer registry members were mailed an informational letter inviting them to
join an OSG for cancer patients and survivors. Included was information regarding their
ability to sign up or opt-out at anytime of future contact. One week following the
mailing of the letter, research assistants attempted to verbally recruit cancer registry
patients by phone. Participants who were reached within three to five phone calls were
invited to participate in the study. During the phone call, participants first were briefly
informed about the nature of the study and screened based on the eligibility criteria.
Those who passed screening were informed of the basic features of the website, how to
make the most of their experience, and questionnaire and participation expectations.
Patients who verbally consented were signed-up for the online support group, allowed to
select a username and password, and automatically emailed an informational letter with
a link to access the support group. Lastly, they were instructed to read the informed
consent page that would appear upon logging into the website and told that they could
opt-out of further contact, and that consenting or declining would have no impact on
their medical treatment or relationship with their physicians.
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Nationwide Recruitment
Cancer patients were recruited nationwide via a number of different methods.
Physicians, social workers, and marriage and family therapists were mailed informative
packets that included advertisement flyers that could be posted in offices. Additionally,
flyers, newspaper advertisements, public service announcements, and Internet-based
advertising were used to recruit patients. These advertisements directed patients to the
website where they could learn more information and automatically enroll themselves in
the OSG.

All Participants
Once patients logged into the confidential OSG, they are automatically directed
through a series of screens. First, the consent form appears and patients have the option
to agree or decline. Second, a baseline questionnaire appears and must be completed
before a participant receives information regarding their randomization status. After
questionnaire completion, participants are informed whether they are randomized into
the immediate treatment group or 12-week wait-list, control group. The treatment group
is asked to complete a questionnaire two weeks later, and at three and six months postbaseline. The control group is asked to complete a second survey at the end of their 12week wait, a questionnaire two weeks later, and then at three and six months postbaseline. Participants are reminded to complete questionnaires by email prompts,
phone calls, and were mailed questionnaires with a stamped return envelope if a
questionnaire had not been completed at four weeks post-due date. Each participant was
mailed a $10 reimbursement and thank you note for each questionnaire completed.
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Measures
OQ
Psychological disturbance will be measured using the OQ-45 (Lambert, et al.,
2004). The OQ-45 measures the global functioning of a client and is composed of three
subscales that measure subjective discomfort (intrapsychic functioning), interpersonal
relationships, and social role performance. The OQ-45 has adequate internal
consistency (α = .93) and test-retest reliability (r = .84) (Lambert, et al., 2004). A
number of studies have examined the validity of the OQ. It has also been found to be
sensitive to change over brief periods of time in treatment populations, while remaining
the same in untreated people (Vermeersch, et al., 2000). Umphress and colleagues
(1997) concurrent validity criterion measures included the GSI, IIP, and SAS-revised.
While the OQ total and Symptom Distress subscale scores correlated as predicted with
the respective criterion measures (Total OQ: r = .66-.88, Symptom Distress: r = .65-.92),
the Interpersonal Relationships and Social Role subscales did not have the strongest
magnitude with their predicted measure, despite their significant validity coefficient
scores across measures (Interpersonal Relationships: r =.45-.69; Social Role: r =.53.73).

Distress Thermometer
The DT (Roth, et al., 1998), a one-item measure, reads, “How distressed have
you been during the past week on a scale of 0 to 10,” and depicts a visual thermometer
with a 0–10 scale that ranges from “no distress” (0) to “extreme distress” (10).
Significant distress is indicated by scores of four or higher. Mild distress ranges from
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four to five, moderate distress ranges from six to seven, and eight or more is considered
severe distress. A comprehensive review of the SE, SP, positive predictive value
(PPV), and negative predictive value (NPV) supported its performance when examining
distress but not anxiety or depression (Mitchell, 2007). Specifically, for distress the
study found an SE of 77.1%, SP of 66.1%, PPV of 55.6%, and NPV of 84.0%.
However, for anxiety the SE was 77.3%, SP 56.6%, PPV of 55.2%, and an NPV of
80.25%. When measuring depression, the SE was 80.9%, SP of 60.2%, PPV of 32.8%
and NPV of 92.9%.

Fact-G
The FACT-G scale (Cella, et al., 1993) is a 28-item general cancer QOL measure
that results in a total score as well as subscales for physical, functional, social, and
emotional well-being along with satisfaction with treatment relationship. Test-retest
reliability for the scales is the following: physical well-being (.88), functional well-being
(.84), social well being (.82), emotional well-being (.82), satisfaction with physician
relationship (.83), and total score (.92). Validity was supported by hypothesized
convergent and divergent validity scores with criterion measures. Convergent validity
was demonstrated by the total score correlation with the Functional Living Index-Cancer
(r =.79), Brief Poms (r = -.65), and Taylor Mass Anxiety Scale (r = -.58). However,
correlation with social desirability, as measured by the brief M-CSDS, was low (r = .22).
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CES-D
The CES-D (Radloff, 1977) utilizes 20 items on a four-point Likert scale to
examine depressive symptoms in individuals. Previous research has validated it for
widespread use in cancer populations (Hann, Winter, & Jacobsen, 1999). Validity
studies have found good levels of relationship between the CES-D and other depression
rating scales including the following: the Hamilton rating scale (r = .50s to .80s), the
Raskin rating scale (r = .30s to .80s), the Lubin Depression Adjective Checklist (r = .40s
to .50s) (Locke & Putnam, Unknown). A previous lung cancer study has found it to
have good reliability with this population (α = .79; Sanders, et al., 2009).

Brief POMS
The brief POMS is a 37-item shortened version of the original 65-item scale that
attempts to identify mood states. By utilizing a five-point-Likert-scale to endorse mood
adjectives from “not at all” to “extremely,” participants are classifying moods across
six-factors: tension-anxiety, depression-dejection, anger-hostility, and confusionbewilderment. Total mood score is determined by subtracting vigor-activity from the
sum of the other five scales. Cronbach’s alpha ranges from .78 to .91 for each of the six
subscales and for the total score. Convergent and divergent validity were demonstrated
by hypothesized correlations between the following: the POMS depression subscale and
total score and the CES-D (both .63); the POMS fatigue and vigor subscales with the
Self-Rated Karnofsky (-.40. to .39); the POMS fatigue and vigor subscales with the
MOS SF-20 Physical Functioning (both -.42); the POMS-vigor scale and the Bradburn
Positive Affect Scales (.53); the POMS total score and the Bradburn Negative Affect
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Scales (.60); and low correlations between the POMS anger, confusion, depression, and
tension subscales with the MOS SF-20 Physical Functioning and the Self-Rated
Karnofsky (-.08 to -.20). Additionally a CFA supported the six-factor structure of the
POMS (Baker, Denniston, Zabora, Polland, & Dudley, 2002).

Social Support Scale
The six-item social support scale is a combination of two, 3-item subscales
drawn from the 29-item Yale Social Support Index. The Positive Emotional Support
(PES) subscale and Aversive Emotional Support (AES) scale assess the quantity and
quality of social support and interaction on a four-point Likert scale. Construction of
items on these subscales was standardized per item in order to allow items to be
aggregated onto the appropriate scale. A prior study conducted by Butler, Koopman,
Classen, and Spiegal (1999) has utilized these subscales and found Cronbach alpha at
.71 for the PES, and .68 for the AES. Although the validity coefficients could not be
found, these subscales have also been utilized in Koopman et al. (1998).

Social Constraint Scale
The Social Constraint Scale (S.J. Lepore & Ituarte, 1999) is a 15-item measure that
assesses social constraints, specifically with “friends and family” in this version, on
disclosure of distressing feelings and thoughts related to cancer. On a four-point Likert
scale participants rate a variety of social constraint experiences in the prior four weeks.
The coefficient alpha has ranged from .89 to .92. This measure has been found to have
good convergent validity with the Mental Health scale from the MOS-SF36, as well as
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the Negative Affect scale from the PANAS. Additionally, divergent validity is
supported, for the scale was generally not significantly associated with the amount of
social support received as measured by the UCLA social support scale (S.J. Lepore,
2001).

IES-R
The IES-R (Weiss & Marmar, 1996) assessed the post-traumatic emotional
reactions of patients dealing with their cancer diagnosis and symptoms. The measure
includes 22 items, three subscales (intrusiveness, avoidance, and hyperarousal scale),
and a five-point, Likert-scale format. Good reliability was found in a previous lung
cancer research study (α = .89; Sanders, et al., 2009). The IES-R has been utilized in a
variety of cancer-related studies (Lindberg & Wellisch, 2004; Mehnert & Koch, 2007;
Sanders, et al., 2009) and has been found to be highly valid. The PTSD Checklist and
IES-R correlate at high levels (r = .84) demonstrating convergent validity (Creamer,
Bell, & Failla, 2003).

Data Analysis
Aim One
The first aim of the current study was to demonstrate the reliability of the OQ in
a cancer population. This was examined by a Cronbach’s alpha analysis for the OQ
Total score and 3 subscale totals of the OQ. Cronbach’s alpha was ranked according to
guidelines supplied by George and Mallery (2003): > .9 excellent, > .8 good, > .7
acceptable, > .6 questionable, > .5 poor, and < .5 unacceptable (p. 231).
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Aim Two
The second aim of the current study was to demonstrate the concurrent and

Hypothesized Absolute Value of
Convergent andDivergent Validity

construct validity of the OQ in a cancer population (see Figure 1).
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Figure 1. Hypothesized absolute values of convergent and divergent validity for the OQ
Total Score, Symptom Distress, Interpersonal Relationships, and Social Role scales.
DT= Distress Thermometer; FACT-G= Functional Assessment of Cancer Therapy –
General; CES-D= Center for Epidemiologic Studies Depression Scale; POMS= Profile
of Mood States; SSS= Social Support Scale; SCS= Social Constraint Scale; IES-R=
Impact of Event Scale-Revised.

Concurrent validity was examined via significant correlations (p < .05) between the OQ
total score and DT and FACT-G; the Symptom Distress subscale and the CES-D and
Brief POMS; the Interpersonal Relationships subscale and the Social Support Scale and
the FACT-G; and the Social Role subscale with the Social Constraint Scale and FACTG. Divergent validity will be supported by insignificant correlations (p > .05) between
the OQ Total score and the Impact of Events Scale; the Symptom Distress subscale and
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Social Constraint Scale; the Interpersonal Relationships subscale and the CES-D; and
the Social Role subscale with the Brief POMS. Power was calculated via G*Power for
bivariate normal correlations with ∝= .05, two-tailed test, power = .80, correlation p
(Ho) =0.00. The sample size required 84 participants in order to be adequately powered
for r > .30.
Further construct validity of the three domains of the OQ was examined by
conducting an exploratory factor analysis. Parallel analysis determined the number of
factors extracted as five (Hayton, Allen, & Scarpello, 2004). When the items were refactored, the principle axes method was used, with five factors extracted, Varimax
rotation, and loadings sorted by size while suppressing loadings that were less than .15.
A significant factor must have at least three items that load on or above .30, or it has a
minimum of two variables that load at .50 or greater. If any of these salient items crossload closer than .13 with another item than they are no longer considered salient. If
there are any non-significant factors, the factor number will be reduced by one and the
process will be repeated until there are no trivial factors. If Cronbach’s Alpha is smaller
than .60 for any factor’s set of salient items, the number of factors should will be
decreased by one and then re-factored.

Aim Three
The final purpose of the current study was to show preliminary treatment effects
of using the OQ in a cancer population. This aim was evaluated in two ways. First, all
participants were examined for treatment effects by conducting a repeated measures,
within factors analysis of covariance (ANCOVA) examining the appropriate measures
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from the beginning and completion of treatment (i.e. OSG = Time 1 to Time 2; Wait =
Time 2 to Time 3). Significant measure differences in the direction of improvement
after an OSG intervention were indicated by p < .05. Second, an interaction of
treatment group by time was examined by conducting a repeated measures, betweenwithin factors ANCOVA examining differences between the treatment group (Time 1 to
Time 2) and control group (Time 1 to Time 2). It was expected that there would be a
significant interaction, indicated by p < .05. Also, the treatment group should have
significantly lower Time 2 scores than the control group. Power was identical for both
ANCOVAS, and was examined for repeated measures, within-between interaction as
well as a within-interaction. Using G*Power, the following were used for the a-priori
power analysis: F test family, effect size (f)2 = .25, alpha error probability = .05, power
= .80, with two groups, two times of measurement, and a correlation among repeated
measures of .50. In order to meet critical F = 4.15, the sample size would need to be 34.
Our current sample size exceeds this requirement.
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CHAPTER THREE
RESULTS
Characteristics of Participants
Characteristics of participants are presented in Table 1. A majority of
participants identified themselves as White (86.3%), female (69.8%), and married
(68.1%). Participants averaged a mean age of 52.7 years with 15.4 years of education,
and had a 5% trimmed median household income of $62,500. The highest number of
participants reported not knowing their cancer stage (25.3%), followed by Stage II
(20.9%); suffered from breast (28%) or prostate (17%) cancer; and received surgery as
treatment (67%). Moderate to significant distress (DT: x̅ =6; OQ: x̅ = 69) was average.

Table 1
Characteristics of Participants
Participant Characteristics (N = 182)

x̅ (sd)

Age (years)

%

52.7 (11.8)

Gender (% Female)
Education (In Years)
Ethnicity
White
Other
Latino
African American
Asian
Income (Median)
Marital Status
Married
Single
Divorced

69.8
15.4 (2.5)
86.3
4.9
4.4
3.3
1.1
$62,500 ($57,313)
68.1
14.8
13.2
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Table 1. Continued.
Widowed
3.8
Cancer Stage
I
16.5
II
20.9
III
18.1
IV
14.3
Insitu
4.9
Unsure
25.3
Cancer Type
Breast
28.6
Prostate
17.2
Thyroid
7
Female Reproductive (ovarian)
6.6
Melanoma
2.6
Blood/Leukemia/Lymphoma
5
Bladder/Kidney
1.5
Colon/Rectum
3.0
Lung
2.5
Multiple
3.0
Other
23
Cancer Treatment
Bio (?)
3.3
Chemotherapy
42.9
Hormone Therapy
17
Immunotherapy
4.4
Surgery
67
Xrt
47.8
Outcome Questionnaire (0-180, >63 distress)
Total Time 1
69.3 (21.8)
Symptom Distress
41.4 (14.3)
Interpersonal Relationships
16.3 (6.6)
Social/Role Functioning
11.6 (4.3)
Distress (1-10; > 4 = distress)
6 (2.2)
FACT-G Total (0-108; lower = lower QOL)
64.8 (18.4)
CESD Total (>16 cutoff for depression)
22.5 (11.9)
POMS Total (0-124; higher = higher
37.7 (28.8)
distress)
SSS Total (6-24; higher = higher support)
17.9 (3.2)
SCS Total (15-60; higher = more constraint)
29.5 (11.5)
IES-R Total (0-88; higher = more neg)
26.2 (15.8)
Note. XRT= External Beam Radiation Therapy; FACT-G= Functional Assessment
of Cancer Therapy – General; CES-D = Center for Epidemiologic Studies
Depression Scale; POMS= Profile of Mood States; SS= Social Support Scale; SCS=
Social Constraint Scale; IES-R = Impact of Event Scale-Revised.
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Aim One: Reliability of the OQ
The OQ Total Score demonstrated excellent reliability (α = .92). However, the
subscales varied in the quality of their reliability ratings. Whereas the Symptom
Distress scale exemplified excellent reliability (α = .91), the Interpersonal Relationships
only showed good/acceptable reliability (α = .80), and the Social Role displayed poor
reliability (α = .59).

Aim Two: Concurrent and Construct Validity of the OQ
Concurrent Validity
Validity coefficients for the OQ Total Score, Symptom Distress, Interpersonal
Relationships, and Social Role subscales with the DT, Fact-G, CES-D, Brief POMS,
SSS, SCS, and IES-R, may be viewed in Table 2. All criterion measures were
significantly correlated with the OQ Total, Symptom Distress, Interpersonal
Relationships, and Social Role scores. The OQ Total (r = .836) and Symptom Distress
(r = .836) subscale scores were most highly associated with depression (CES-D),
whereas Interpersonal Relationships correlated most strongly with social support (SSS: r
= -.643) and the Social Role with negative moods (Brief POMS: r = .525).

52

Table 2
Intercorrelations for OQ Scores and Patient Reported Outcome Measures
V
1
2
3
4
5
6
7
8
9
10
11

1

2

3

4

5

6

7

8

9

10

11

1
.947

1

.792

.605

1

.690

.538

.457

1

.592

.581

.481

.348

1

-.795

-.778

-.639

-.464

-.568

1

.836

.836

.633

.510

.611

-.835

1

.831

.831

.606

.525

.603

-.821

.889

1

-.586

-.467

-.643

-.452

-.289

.554

-.466

-.439

1

.637

.632

.508

.366

.338

-.637

.630

.594

-.578

.664

.700

.414

.419

.524

-.657

.714

.696

-.312

1
.572

1

Note. V= Variable; 1= OQ Total; 2=OQ SD; 3=OQ IR; 4=OQ SR; 5=DT; 6=Fact-G;
7=CES-D; 8=Brief POMS; 9=SSS; 10=SCS; 11=IES-R. All correlations = p < .001.

A graphic representation of the outcome of the convergent and divergent validity
of particular hypothesized measures may be seen in Figure 2. Convergent validity was
demonstrated across all measures for the OQ Total, Symptom Distress, Interpersonal
Relationships, and Social Role scores; however, divergent validity was not
demonstrated.
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Absolute Value of Validity Coef:icients
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Figure 2. Absolute values of validity coefficients for the OQ Total Score, Symptom
Distress, Interpersonal Relationships, and Social Role scales. DT=Distress
Thermometer; FACT-G= Functional Assessment of Cancer Therapy – General; CESD = Center for Epidemiologic Studies Depression Scale; POMS= Profile of Mood
States; SSS= Social Support Scale; SCS= Social Constraint Scale; IES-R = Impact of
Event Scale-Revised.

Construct Validity
Parallel analysis determined the number of factors extracted as five (Hayton,
Allen, & Scarpello, 2004). When the items were re-factored, the principle axes method
was used, with five factors extracted, Varimax rotation, and loadings sorted by size
while suppressing loadings that were less than .15. Varimax rotation was selected
because it forces items to be uncorrelated and thus most clearly defines the structure of a
factor conceptually. The loadings were ordered by size for ease of viewing, and
loadings under .15 were suppressed because they were the most insignificant.
Significant factors were required to have at least three items that load on or above .30 or
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have a minimum of two variables that load at .50 or greater. If any salient items crossloaded closer than .13 with another item than they were no longer considered salient.
For factors that did not meet the minimal significance criteria, the factor number was
reduced by one and the process was repeated until there were no trivial factors. If
Cronbach’s Alpha was smaller than .60 for any factor’s set of salient items, the number
of factors was decreased by one and then re-factored. Through this process five factors
were reduced to three significant factors (see Table 3). The three factors differed from
the original three factor subscales and were renamed the following: Factor 1, Sense of
Well-being; Factor 2, Symptom Distress; Factor 3, Externalizing Behaviors.

Table 3
Means, Standard Deviations, Rotated Factor Loadings, and Communalities for OQ
Items
Factor Loadings
h
1
2
3
.770 .782 .252
2

Item (Prior Factor Subscale)
31 (SD): I am satisfied with my life

x̅
1.85

SD
1.053

13 (SD): I am a happy person

1.44

.902

.682 .724

20 (IR): I feel loved and wanted

1.47

1.041

.668 .719

43 (IR): I am satisfied with my
relationships with others
37 (IR): I feel my love relationships
are full and complete
24 (SD): I like myself

1.45

.951

.644 .696

1.91

1.359

.629 .670

1.48

.975

21 (SR): I enjoy my spare time

1.63

1.044

.594 .647

12 (SR): I find my work/school
satisfying
15 (SD): I feel worthless

1.78

1.203

.636 .563 .162 -.186

1.41

1.033

.639 .509 .440

.63

.824

1 (IR): I get along well with others
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.162

.676 .651 .187

.523 .505

.203

Table 3. Continued.
7 (IR): I feel unhappy in my
marriage/significant relationship
30 (IR): I have trouble getting along
with friends and close acquaintances
8 (SD): I have thoughts of ending my
life
17 (IR): I have an unfulfilling sex life

1.56

1.257

.544 .447 .218

1.00

.789

.531 .421 .247

.57

.864

.450 .397 .190

2.43

1.338

19 (IR): I have frequent arguments

1.31

.903

.458 .313 .226

42 (SD): I feel blue

1.98

.986

.707 .345 .698

9 (SD): I feel weak

2.04

1.132

.707 .192 .655 -.158

36 (SD): I feel nervous

1.78

1.082

.566 .185 .603

10 (SD): I feel fearful

1.90

1.028

.603

22 (SD): I have difficulty
concentrating
23 (SD): I feel hopeless about the
future
41 (SD): I have trouble falling asleep
or staying asleep
2 (SD): I tire quickly

2.27

1.047

.630 .261 .597

1.86

1.096

.676 .479 .566

2.30

1.317

.478

.562

2.50

.911

.664

.554 -.263

33 (SD): I feel that something bad is
going to happen
6 (SD): I feel irritated

1.73

1.089

.635 .252 .548

2.23

.857

.635 .351 .535

34 (SD): I have sore muscles

2.15

1.093

.519

40 (SD): I feel something is wrong
with my mind
5 (SD): I blame myself for things

1.47

1.133

.589 .367 .501

2.07

1.031

.588 .356 .494

29 (SD): My heart pounds too much

1.24

1.067

.407

3 (SD): I feel no interest in things

1.90

.943

.615 .431 .490

18 (IR): I feel lonely

2.06

1.079

.630 .420 .462

16 (IR): I am concerned about family
troubles
27 (SD): I have an upset stomach

2.30

1.111

.435 .244 .437

1.54

1.103

.424

25 (SD): Distrubing thoughts come
into my mind that I can’t get rid of
45 (SD): I have headaches

1.59

1.085

.539 .220 .401

1.40

1.094

.437
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.257

.435 .348
.210

.222

.599
.196

.293

.525

.491

.420

.339

.152

.153

Table 3. Continued.
28 (SR): I am not working/studying as
well as I used to
35 (SD): I feel afraid of open spaces,
or driving, or being on buses,
subways, and so forth
11 (SD): After heavy drinking, I need
a drink the next morning to get going
32 (SR): I have trouble at work/school
because of drinking or drug use
26 (IR): I feel annoyed by people who
criticize my drinking (or drug use)
39 (SR): I have too may disagreements
at work/school
44 (SR): I feel angry enough at
work/school to do something I may
regret
4 (SR): I feel stressed at work/school
38 (SR): I feel that I am not doing well
at work/school
14 (SR): I work/study too much

2.03

1.140

.530

.310

.164

.50

.860

.363

.261

.249

.15

.457

.614

.653

.08

.324

.622

.637

.20

.621

.550

.549

.62

.740

.541 .242

.525

.36

.715

.524 .280

.516

2.05

1.112

.618

.378

.435

1.38

1.086

.586 .157 .201

.389

1.69

1.180

.428 -.211

.315

Note. Boldface indicates highest factor loadings. Factor 1 = Sense of Well-Being;
Factor 2 = Symptom Distress; Factor 3 = Externalizing Behaviors; OQ = Outcome
Questionnaire; h2= Communality.

Aim Three: Preliminary Treatment Effects
Finally, a series of repeated measure ANCOVAs were conducted in order to
examine whether the OQ can indicate preliminary treatment effects of an OSG in a
cancer population. This aim was evaluated in two ways. First, to discern if the OQ can
detect a difference over time, all participants, regardless of level of engagement in the
support groups, were evaluated for improvement from baseline to post-treatment while
controlling for health status. Secondly, analyses were conducted to determine if the OQ
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could distinguish the difference between a treatment and control group when controlling
for health status.

Improvement Post-Treatment
First, all participants, regardless of treatment condition or level of engagement in
OSG, were examined for treatment effects over time by conducting a repeated measures
ANCOVA. The repeated measures ANCOVA examined the participant scores from
baseline to post-treatment with perceived physical well-being, as measured by the
FACT-G physical well-being subscale, used as a covariate. Table 4 can be consulted for
baseline and post-treatment OQ means and standard deviations for all participants.
Greenhouse-Geisser was used as a significance level due to Mauchly’s Test of
Sphericity not being valid. As seen in Table 5 and Figure 3, there was a significant
decrease in distress as measured by the OQ from Time 1 to Time 2, F (1, 60) = 5.78, p =
.019.

Table 4
Means and Standard Deviations for Two Treatment (Tx) Groups and Repeated Testing
Times of the OQ

Tx Group (n)
All Participants (63)

Pre-Tx
x̅
SD
NA
NA

Baseline:
OQ Total Time 1
x̅
SD
66.92
25.56

Experimental (46)

NA

72.09

24.30

62.61

23.52

52.94

24.23

52.53

22.21

Control (Pre-tx and
T1 = 48; T2 = 17)

NA

62.63 19.10
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Post-tx:
OQ Total Time 2
x̅
SD
59.89
23.43

Table 5
Effect of Time on OQ Scores While Controlling for FACT-G Physical Well-Being (PWB)
Source

df

Type III SS
Within Subjects

MS

F

Time

1

573.69

573.69

5.78*

Time x FACT-G
PWB
Error

1

189.90

189.90

1.91

61

6059.07

99.33

Between Subjects
FACT-G PWB
Error

1

114226.94

114226.94

61

45542.35

746.60

153.00***

Note. *p < .05, ** p < .01, ***p < .001. Time= Baseline (1) and Post (2) Treatment.

Total OQ Score
68
66
64
62

Total OQ Score

60
58
56
Time 1

Time 2

Figure 3. All participants Total Mean OQ scores from Time 1 to Time 2 while
controlling for Fact-G physical well-being (x̅ = 19.12).
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Interaction of Treatment Group by Time
Next, the data was analyzed in order to discern if the OQ can detect not only a
difference over time, but also to distinguish significance of the experimental group that
received treatment when compared to a control group over time. An interaction of
treatment group by time was examined by conducting a repeated measures, betweenwithin factors ANCOVA examining differences between the treatment group (baseline
to post-treatment) and control group (pre-treatment to baseline) while covarying for selfperceived level of physical well-being as measured by the FACT-G physical well-being
subscale.
Some assumptions of a repeated measure ANCOVA were examined before
results were interpreted. First, homogeneity of variance across levels of treatment
groups was assessed using Box’s M Test. Since Box’s M was significant (p = .002),
indicating that the variance across levels of treatment may not be the same, Levene’s
tests were examined for significant inequality across the dependent variables. Since
neither Levene’s test was significant for either univariate analysis for OQ Time 1 (p =
.59) or 2 (p = .40), it was decided that equality could be assumed and that likely
hypersentivity of Box’s M lead to its flagged significance. Thus, the model results were
still examined. Greenhouse-Geisser was used as a significance level due to Mauchly’s
Test of Sphericity not being valid. Table 6 records the findings. Again, there was as a
significant decrease in distress over time, regardless of level of treatment group F (1, 90)
= 14.99, p < .001. Additionally, those with worse health status showed a significant
change over time F (1, 90) = 7.48, p = .008. However, no interaction between treatment
condition and time was indicated by these results (see Table 6 and Figure 4).
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Table 6
Effect of Treatment Condition Over Time on OQ Scores While Controlling for FACT-G
Physical Well-Being (PWB)
Source

df

Type IV SS
Within Subjects

MS

F

Time

1

2059.79

2059.79

14.99***

Time x FACT-G PWB

1

1027.47

1027.47

7.48*

Time x Tx Condition

1

37.96

37.96

.60

91

12508.77

137.46

Error

Between Subjects
FACT-G PWB

1

127747.19

127747.19

201.68***

Tx Condition

1

1163.08

1163.08

1.84

91

57640.53

633.41

Error

Note. *p < .05, ** p < .01, ***p < .001.

80
70
60
50
40
30

Experimental Group

20

Control Group

10
0
Time 1

Time 2
Total OQ Score

Figure 4. Effect of time on treatment level for Total Mean OQ scores while
controlling for Fact-G physical well-being (x̅ = 19.12).
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Post-Hoc Analyses
Although it was not demonstrated that treatment condition impacted outcome, it
was believed this may have been due to an additional variable, engagement. Participant
engagement in the treatment varied greatly due to self-selection. Specifically,
engagement in the experimental group was measured in the following ways: time in
seconds on support group website, number of discussion board posts, number of emails
sent, number of blogs posted, number of live support group chats attended, time in
seconds in live support group chat, and total chat word count (please see Table 7).
Because these variables were highly positively skewed (range= 2.82 to 5.53) with a
great degree of kurtosis (range= 7.70 to 42.00), the variables were computed for the log
of their original score and transformed. This procedure created more normally
distributed variables that were used in all later analyses (skew range = -.63 to .72;
kurtosis range= -1.48 to -.31).

Table 7
Characteristics of Participant Engagement (Log)
Engagement (N = 182)

x̅

M

%>0

11722.60

1752.50

100%

Discussion Board Posts

1.82

0

29.1%

Emails sent

2.53

0

33%

Blogs Posted

1.42

0

22.4%

Live Support Group Chats Attended

0.82

0

20.3%

11024.82

0

29.1%

466.68

0

25.3%

Time on Website (Seconds)

Time in Live Support Group Chat (Seconds)
Total Chat Word Count
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To determine which engagement variables specifically correlated the greatest
with improvement in OQ distress scores (from baseline to post-treatment), a correlation
was conducted (See Table 8). Based on these findings, it appears that change in OQ
score, or positive improvement in distress, is most positively associated with the total
time spent engaging with the intervention (r = .313, p < .01).

Table 8
Correlations Between Change in OQ Score and (Log of) Engagement (N = 182)
Variable

1

1. OQ
Change

1

2. Total
Time
3. DB
Posts
4. Emails
5. Blogs
Posted
6. #
Chats
Attended
7. Chat
Time
8. # Chat
Words

2

3

4

5

6

7

.313**

1

.057

.688***

1

.039

.737***

-.014

.452**

.627**
*
.407*

1
.397*

.153

.724***

.502**

.458**

.184

1

-.031

.668***

.350*

.397**

.237

.625***

1

-.185

.667***

.343*

.501**

.305

.644***

.876***

Note. *p < .01; ** p < .001; *** p < .0001.
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8

1

1

Thus, another repeated measures ANCOVA was conducted. The repeated
measures ANCOVA examined the participant scores from baseline to post-treatment
with perceived physical well-being, as measured by the FACT-G physical well-being
subscale, and engagement, as measured by total time spent utilizing the intervention,
used as covariates. Because Mauchly’s test of sphericity was invalid, GreenhouseGeisser significance levels were noted in Table 9 below. This time it was shown that
those who engaged more with the OSG improved over time F (1, 59) = 6.00, p = 0.018.

Table 9
Effect of Time on OQ Scores While Controlling for FACT-G Physical Well-Being (PWB)
and Engagement
Source

df

Type IV SS
Within Subjects

MS

F

Time

1

35.44

35.44

.386

Time x FACT-G PWB

1

128.471

128.471

1.40

Time x Engagement

1

550.97

550.97

6.00*

60

5508.10

91.80

Error

Between Subjects
FACT-G PWB

1

20628.53

20628.53

29.88***

Engagement

1

4120.29

4120.29

5.97*

60

41422.06

690.37

Error

Note. *p < .05, ** p < .01, ***p < .001.
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OQ Interpretability
Based on the previously discussed standards the OQ was interpreted in four
major categories. The greatest number of patients were categorized as no change
(56.5%), followed by recovered (21%), improved (14.5%), and deteriorated (8.1%). Of
those in the treatment group, the majority were categorized as no change (56.5%, n=6),
followed by recovered (23.9%, n=11), improved (8.9%, n=8), and lastly deteriorated
(2.2%, n=1). Of those in the control group, the majority were also considered to be in
the no change category (56.3%, n=9), followed by deteriorated (25%, n=4), then
recovered (12.5%, n=2), and finally improved (6.3%, n=1).
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CHAPTER FOUR
DISCUSSION

This study examined the suitability of the use of the OQ as a PRO in a
heterogeneous cancer population. As noted previously, Luckett and colleagues (2010)
suggested the following categories for the evaluation of instrument quality: examination
of the content, psychometric properties, track record, interpretability, and practical
issues. These issues will be elucidated and summarized. Overall, the results show
mixed support for the implementation of the OQ as a PRO in a chronic disease sample.
Generally, if the OQ is to be used as is within a cancer population, the Total Score may
be interpreted as both reliable and valid and able to demonstrate treatment effects in a
cancer population, but the subscale scores should not be interpreted.

OQ Content and Psychometric Properties

Content
The OQ item content was considered suitable (face valid) for a heterogeneous
cancer population. More so than other PROs, this scale’s content can determine both
psychological distress and global functioning. Thus, this measure has a high level of
face validity for its items.

Reliability
Consistent with the previous research in general psychiatric populations and the

66

present study’s hypotheses, the OQ Total Score and Symptom Distress subscale
demonstrated excellent reliability and the Interpersonal Relationships revealed
good/acceptable reliability. However, in this study’s sample, the Social Role’s
reliability was rated as poor although it had measured more highly as
acceptable/questionable in prior findings. Consistently between present and previous
findings the Social Role scale is the least reliable of the three subscales.
Present results may indicate that either there is a problem with the items that
construct the Social Role scale or that these results indicate that the social role questions
were likely not answered as reliably by cancer patients. It is noted by the researcher that
some patients verbally commented or transcribed on their PRO that they were confused
at how to best answer questions regarding their functioning at work or school (despite
the instructions clarifying this issue) because they were unemployed or taking a leave of
absence due to health status but also had co-occurring mental health issues. However,
perhaps a more clearly defined set of items would clarify this issue and increase the
reliability of these items.

Validity

Concurrent Validity
Concurrent validity findings were mixed for the OQ within this mixed cancer
population. As hypothesized, convergent validity was demonstrated across the OQ
Total Score and subscales. Although the OQ Total Score did indeed correlate with its
criterion measures (DT and Fact-G), it was associated the most strongly with the CES-

67

D. Upon examination, the OQ Total score is highly correlated with the Symptom
Distress subscale. The Symptom Distress scale, as predicted, was associated most
strongly with the CES-D as well as the Brief POMS. Likewise, the Interpersonal
Relationships subscale also correlated the most strongly with its predicted measures, the
Fact-G and the SSS. Unlike the other subscales, the Social Role subscale did not
correlate strongly with its predicted criterion measures. While it was significantly
associated with the Fact-G and SCS, it correlated the most strongly with the Brief
POMS.
There are several potential explanations for why the OQ Total Score and Social
Role subscale may not have correlated strongly with their criterion measures. The OQ
Total score may attempt to measure general distress and well-being using three
subscales, but the total score is so highly associated with the Symptom Distress subscale
in this population that it is driven by scores on this subscale which highly correlate with
the CES-D. Additionally, the Social Role subscale was more strongly associated with
mood states (Brief POMS) instead of physiological difficulties in completing tasks,
which the Social Role subscale items also measure.
Despite hypothesized divergent validity, the OQ Total Score and subscales were
significantly correlated with each measure selected. This is likely due to the
researcher’s poor selection of divergent measures due to underestimation of how highly
correlated the domains of symptom distress, interpersonal relationships, and social roles
can be. Support for this rationale is indicated by the significant correlations between the
DT, FACT-G, CES-D, Brief Poms, SSS, SCS, and IES-R with all measures as well.
The researcher selected divergent criterion measures based on the assumption that the
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subscales of the OQ would represent separate factors and thus not be highly correlated.
These findings suggest that the current factor structure of the OQ, which is widely used
in general outpatient psychotherapy settings, may not generalize well to use in cancer
survivors.

Construct Validity
As hypothesized, the current factor structure of the OQ was not supported by this
study, and a differing three-factor model was identified via exploratory factor analysis.
However, a larger sample size is needed to confirm the new factors identified in this
study. This new three-factor model has the following labels: Sense of Well-Being,
Symptom Distress, and Externalizing Behaviors. The 15-item Sense of Well-Being
factor included items that were generally positively worded, i.e. “I am satisfied with my
life, ” and included items mainly from the prior Symptom Distress and Interpersonal
Relationships subscales (13 of 15-items). The 22-item Symptom Distress subscale
included items that generally reflected symptoms or negative life events such as “I feel
blue” and generally reflected the previous Symptom Distress subscale items (19 of 22
items). The eight-item externalizing behaviors subscale included substance abuse items
and anger and is mainly composed of the previous scale’s Social Role items (six of eight
items). These newly created factors demonstrated at minimum acceptable reliability and
were forcibly uncorrelated due to the Varimax rotation.
Prior literature reflects the likelihood that a new factor structure would be
necessary, for the pervious articles cited that the current three-factor model was poorlyfitting and requested exploratory factor analysis to be conducted to further elucidate the
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domains and subscales exemplified in the OQ. It is likely that the highly correlated
nature of the OQ’s subscale domains lead to trouble with these original three factors.
This makes subscale interpretation of scores difficult. If the OQ is to be used in a cancer
population, only the Total Score should be interpreted as valid. Further research should
attempt to confirm the factor structure identified here in other populations, both cancer
and psychiatric, before being generalized.

OQ Track Record
As hypothesized, the current study indicated that the OQ was able to demonstrate
preliminary treatment effects in a RCT of cancer patients engaging in an OSG. Many
previous studies that demonstrated the OQ’s track record implemented a more complex
OQ-feedback system that incorporated the use of the previously mentioned algorithm
that assesses progress and change and flags cases that may not be on track for
improvement (e.g., Hawkins, Lambert, Vermeersch, Slade, & Tuttle, 2004; Lambert,
Whipple, et al., 2001; Lambert, et al., 2002 ; Whipple, et al., 2003). In these studies,
part of the intervention included receiving feedback from the OQ itself. However, the
current study did not focus on a complex flagging system for the OQ-feedback. In this
study, the total OQ scores were viewable by the OSG clinicians, although no effort was
made to emphasize or track whether clinicians noted this score. The primary
intervention was via the online support group.
When all results were taken into account, the OQ was able to demonstrate an
improvement in distress over time for those individuals with a worse perception of their
physical well-being as well as for those who spent more time utilizing the online
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intervention. Interestingly, perception of physical well-being was not related to the
amount of time spent engaging in the intervention (r=-0.015, p= 8.47.)

OQ Interpretability
It is also easy to interpret results based on the reliable change index of four. In
this study it was found that the majority of individuals (56.5%) made no reliable change
in their status. However, 35.5% made a reliable change to recovery or improved by a
clinically significant amount. Importantly, a few participants deteriorated (8.1%).
These numbers are comparable to those found in a meta-analysis of previous OQ studies
(M. J. Lambert, et al., 2003). When a multitude of feedback OQ studies were analyzed
for treatment effects, it was noted that 54.8% made no reliable change, 38.7% made
reliable change of recovery or improvement, and 6.5% of the sample deteriorated.

OQ Practical Issues
This study had less administrator and patient burden than previous studies. The
OQ was easily distributed via an email link. Internet-based point and click answers
were possible on the Likert-type scale. The scale was computer-scored and accessible
via a database as well as linked to support group participants’ profiles. These profiles
were viewable by clinicians treating those in the OSG.

Study Limitations and Strengths
There were many strengths associated with this study as well as some challenges
and areas that could be improved upon. First, this study represented the first attempt to
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examine the reliability and validity of this outcome measure within a cancer population.
Second, this study used a randomized controlled longitudinal design to assess outcomes
in an online support group. However the OQ is a face-valid self-report form, which is
susceptible to all the inherent flaws within this reporting procedure—accuracy, response
bias, etc.
Because participants were required to use the internet for treatment, it is likely
that this study captured data from those who may otherwise not have been able to
participate (the extremely ill or those with difficult work schedules) but may also have
excluded some who would otherwise have participated (those without internet access or
computer literacy). Also, many potential participants were eliminated due to an Englishliteracy requirement. Additionally, there may have been a response bias for those who
chose to respond to the questionnaire when compared with non-responders.
However, because the trial occurred over the internet we were able to capture
behavioral data that may be missed in face-to-face groups, i.e. number of conversations
had with other participants, time spent reading homework, number of words said in
support group, etc. However, the drawback to an online group format was potentially a
lower dose of intervention because individuals could self-select their levels of
engagement within the treatment group. Thus, the dose of intervention was selfdetermined regardless of treatment status. Whereas some participant’s engaged
frequently and often, other participants struggled with attrition and completion of
follow-up questionnaires. This problem significantly and dramatically decreased the
sample size and resulting power for our analyses that included post-test measures and
was a significant challenge throughout the course of the study.
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Future Directions
Ultimately, there are several areas for future directions of this study. First, the
reliability and validity of the OQ should be examined in other cancer populations in
order to demonstrate support for the findings noted here. Specifically, a confirmatory
factor analysis should be utilized within a cancer population to give further evidence to
the three different factors that were identified in this study. Next, other face-to-face or
online studies should examine whether the OQ can demonstrate significance for
outcomes in other cancer support groups.
Another area of interest from this study may be that of the format of the online
support group itself. Further studies should examine ways to improve engagement and
decrease attrition within online support groups. Some questions that may be asked: what
is an essential dose of treatment within an online study for participants to clinically
benefit from it? What types of interventions are the most effective online? What do
people want out of an online support group? What keeps them returning? These are
questions that the future of psychology may quickly need to answer.
Particularly, one way to increase engagement may be feedback of the OQ itself
to online participants. This study did not utilize feedback of the OQ as part of the
intervention. Future studies may attempt to improve treatment effects as well as
engagement by implementing some of the strategies utilized in prior OQ research. This
may include flagging participants who are at risk for not being on track, providing OQ
scores to participants, and helping both clinician and participant visibly see a graph over
time of OQ-change with qualitative understanding of the meaning of the change.
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Summary
This study identified the suitability of the use of the OQ Total Score as a PRO in
a heterogeneous cancer population based on the examination of the content,
psychometric properties, track record, interpretability, and practical issues. Despite
some study limitations, this was the first study of its kind to examine the use of this
measure in a chronic disease population. Future studies may shed some more light on
not only the reliability and validity of this measure, but also ways to improve
engagement and treatment outcomes for cancer populations.
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